What's Happening?
ILiAD Biotechnologies has secured $115 million in Series B funding to advance its BPZE1 vaccine, a new intranasal formulation for whooping cough (Bordetella pertussis). The vaccine, licensed from the Institut Pasteur de Lille and Inserm in France, aims to provide long-lasting protection both mucosally and systemically. This funding comes as whooping cough cases rise in Europe and the U.S., attributed to lower vaccination rates. The company plans to initiate a pivotal human challenge trial later this year, with results expected in 2027. The funding round was led by RA Capital Management, with participation from Janus Henderson Investors, BNP Paribas, and others.
Why It's Important?
The development of BPZE1 is significant as it addresses the growing public health
concern of whooping cough, a disease characterized by severe coughing fits. The needle-free administration of the vaccine could improve vaccination rates, offering a more natural and durable immune response. This development is crucial as current vaccines have seen reduced uptake, leading to decreased population immunity. The successful deployment of BPZE1 could set a precedent for future vaccine innovations, particularly in enhancing public acceptance and compliance.
What's Next?
ILiAD Biotechnologies plans to start a pivotal human challenge trial for BPZE1 later this year, with a readout expected in 2027. The company is banking on the vaccine's needle-free administration to encourage broader uptake. As the trial progresses, stakeholders, including public health officials and the medical community, will be closely monitoring its outcomes. The success of this trial could lead to accelerated regulatory approvals and commercialization, potentially impacting vaccination strategies globally.
